Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8671MR)

This product GTTS-WQ8671MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ8671MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8625MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ14973MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ1690MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ468MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ9449MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ4871MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ5395MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ5995MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO 095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW